Carmot Therapeutics
Carmot Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for metabolic diseases, particularly obesity and diabetes. The company develops incretin receptor modulators including dual GLP-1/GIP receptor agonists and oral GLP-1 receptor agonists.
Acquired
Carmot Therapeutics has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Total Funding
$372M
5 rounds
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $372M across 5 rounds
Last updated 06-25-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 25, 2023 | Series E | $150M | — | Deep Track Capital |
| Jul 26, 2022 | Series D Press release | $160M | — | The Column Group, RA Capital Management |
| Sep 30, 2020 | Series C Press release | $47M | — | Amgen Ventures |
Prominent Investors
Leadership
Stig K. Hansen
Co-founder and Chief Executive Officer
Daniel Erlanson
Co-founder and President
Heather Turner
Chief Operating Officer
Manu Chakravarthy
Chief Medical Officer and Executive Vice President of R&D
Michael Gray
Chief Financial and Operating Officer
James Watson
Chief Business Officer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.